MedTrace Logo

Intrathecal Dexmedetomidine vs Midazolame

NCT06315634 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2024-03-18

No results posted yet for this study

Summary

Prospective Randomized Controlled Clinical Trial to Compare Intrathecal Dexmedetomidine Versus Midazolame in Orthopedic Cancer Surgeries

Conditions

  • Postoperative Pain

Interventions

DRUG

Dexmedetomidine

5 micrograms intrathecal dexmedetomidine

DRUG

Midazolam

2 milligrams intrathecal midazolam

DRUG

Bupivacain

12.5 milligrams 0.5% intrathecal hyperbaric bupivacaine

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Mohamed Elwasef, MD · NCI Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2022-03-10
Completion
2022-03-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06315634 on ClinicalTrials.gov